1-4 of 4
Shiro Oka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Open Access
Subject Area:
Oncology
Yasutoshi Fujii, Tomokazu Kawaoka, Yuki Shirane, Ryoichi Miura, Hikaru Nakahara, Kenji Yamaoka, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Eisuke Murakami, Daiki Miki, Nelson Clair Hayes, Masataka Tsuge, Yuko Nakamura, Kazuo Awai, Shiro Oka
Journal: Oncology
Oncology 1–6.
https://doi.org/10.1159/000542517
Published Online: 11 November 2024
View articletitled, First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Open the PDF for First-Line Durvalumab plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in another window
Journal Articles

Kinesin Family Member B18 Is Related to Gastric Mucin Phenotype and Contributes to Gastric Cancer Progression by Regulating Epithelial-Mesenchymal Transition

Available to Purchase
Subject Area:
Oncology
Akira Ishikawa, Ryo Yasumatsu, Takafumi Fukui, Aya Kido, Narutaka Katsuya, Kazuhiro Sentani, Kazuya Kuraoka, Naohide Oue, Takahisa Suzuki, Shiro Oka, Takahiro Kotachi, Kazuaki Tanabe, Hideki Ohdan, Hassan Ashktorab, Duane Smoot, Wataru Yasui
Journal: Oncology
Oncology (2024) 102 (4): 354–365.
https://doi.org/10.1159/000533791
Published Online: 09 October 2023
View articletitled, Kinesin Family Member B18 Is Related to Gastric Mucin Phenotype and Contributes to Gastric Cancer Progression by Regulating Epithelial-Mesenchymal Transition
Open the PDF for Kinesin Family Member B18 Is Related to Gastric Mucin Phenotype and Contributes to Gastric Cancer Progression by Regulating Epithelial-Mesenchymal Transition in another window
Journal Articles

Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab

Available to Purchase
Subject Area:
Oncology
Chihiro Kikugawa, Shinsuke Uchikawa, Tomokazu Kawaoka, Takahiro Kinami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Masataka Tsuge, Yumi Kosaka, Kazuki Ohya, Nami Mori, Shintaro Takaki, Keiji Tsuji, Hirotaka Kouno, Hiroshi Kohno, Kei Morio, Takashi Moriya, Michihiro Nonaka, Yasuyuki Aisaka, Keiichi Masaki, Yohji Honda, Noriaki Naeshiro, Akira Hiramatsu, Hiroshi Aikata, Shiro Oka
Journal: Oncology
Oncology (2024) 102 (3): 239–251.
https://doi.org/10.1159/000533859
Published Online: 20 September 2023
View articletitled, Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab
Open the PDF for Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus Bevacizumab in another window
Journal Articles

The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib

Available to Purchase
Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates) , Karger e-Journal Backfile Collection 2023 , Oncology
Kikugawa Chihiro, Tomokazu Kawaoka, Shinsuke Uchikawa, Takahiro Kinami, Shintaro Yamasaki, Masanari Kosaka, Yusuke Johira, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Kenji Yamaoka, Yuji Teraoka, Takuro Uchida, Hatsue Fujino, Takashi Nakahara, Atsushi Ono, Eisuke Murakami, Wataru Okamoto, Masami Yamauchi, Daiki Miki, Masataka Tsuge, Michio Imamura, Hiroshi Aikata, Shiro Oka
Journal: Oncology
Oncology (2023) 101 (8): 491–501.
https://doi.org/10.1159/000530991
Published Online: 10 July 2023
View articletitled, The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib
Open the PDF for The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib in another window